Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.


Player Avatar jnpatten (< 20) Submitted: 3/30/2013 7:49:12 PM : Outperform Start Price: $192.99 BIIB Score: +11.71

New drug that was approved could prove to provide huge returns compared to what the market currently offers

Featured Broker Partners